Ozempic One of the Most Prescribed Medications in the United States

Publish Date : 11/19/2024

A recent study estimates that over half of U.S. adults, approximately 136.8 million people, are eligible for semaglutide (Ozempic, Wegovy, Rybelsus) based on its approved indications for diabetes, weight management, and secondary cardiovascular disease (CVD) prevention. This exceeds the number of adults eligible for statins, highlighting semaglutide’s widespread applicability.

Key findings include:

Please feel free to contact a GLP-1 Lawsuit attorney at info@westrikeback.com or 1-877-542-4646. One of our experienced GLP-1 Lawsuit lawyers will help evaluate your claim and explain your legal rights for free. McSweeney / Langevin is providing consultations to individuals throughout the United States. Information provided by email or phone will be kept confidential.

Approximately 39.3 million eligible adults qualify for non-weight management indications, which often have better insurance coverage. However, affordability remains a barrier, with many users reporting difficulty affording GLP-1 receptor agonists.

Semaglutide, approved for type 2 diabetes in 2017, later gained approval for chronic weight management and cardiovascular risk reduction in individuals with obesity or overweight and related conditions. All uses require a reduced-calorie diet and exercise regimen.

With increased popularity of GLP-1 drugs to treat obesity and diabetes, concern has risen that use may come with serious side effects. Our firm is currently investigating GLP-1 lawsuits.

Want to find out if you or a loved one has a GLP-1 claim?

Please feel free to contact a GLP-1 Lawsuit attorney at info@westrikeback.com or 1-877-542-4646. One of our experienced GLP-1 Lawsuit lawyers will help evaluate your claim and explain your legal rights for free. McSweeney / Langevin is providing consultations to individuals throughout the United States. Information provided by email or phone will be kept confidential.

• Weight management: 129.2 million adults are eligible, with 97.5 million qualifying solely for this indication.
• Diabetes: 35 million adults qualify, 7.6 million exclusively.
• Secondary CVD prevention: 8.9 million qualify, all overlapping with other indications.

Approximately 39.3 million eligible adults qualify for non-weight management indications, which often have better insurance coverage. However, affordability remains a barrier, with many users reporting difficulty affording GLP-1 receptor agonists.

Semaglutide, approved for type 2 diabetes in 2017, later gained approval for chronic weight management and cardiovascular risk reduction in individuals with obesity or overweight and related conditions. All uses require a reduced-calorie diet and exercise regimen.

With increased popularity of GLP-1 drugs to treat obesity and diabetes, concern has risen that use may come with serious side effects. Our firm is currently investigating GLP-1 lawsuits.

Want to find out if you or a loved one has a GLP-1 claim?

Please feel free to contact a GLP-1 Lawsuit attorney at info@westrikeback.com or 1-877-542-4646. One of our experienced GLP-1 Lawsuit lawyers will help evaluate your claim and explain your legal rights for free. McSweeney / Langevin is providing consultations to individuals throughout the United States. Information provided by email or phone will be kept confidential.